You are here

Our science / Clinical Trials / Find a Trial / NCT00463918

A Phase I Study to Evaluate the Pharmacokinetics of Multiple Doses of Varenicline in Healthy Adolescent Smokers

Back to Search Print Save as PDF Bookmark Trial

NCT00463918

Last updated on February 18, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Anniston, Alabama, 36201 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Smoking Cessation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
12-16 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy male and female adolescents (12 - 16 years inclusive) with a total body weight
greater than 30 kg who currently smoke an average of at least 3 cigarettes per day.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Male and female subjects with a positive urine drug screen and female subjects with a
positive pregnancy test.

NCT00463918
Pfizer
Completed
A Phase I Study to Evaluate the Pharmacokinetics of Multiple Doses of Varenicline in Healthy Adolescent Smokers

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Smoking Cessation
An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation
NCT00143325
All Genders
18+
Years
Multiple Sites
Smoking Cessation
Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders
NCT01456936
All Genders
18+
Years
Multiple Sites
Smoking Cessation
A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Patch Applied To The Skin
NCT01013454
Males
18+
Years
Bruxelles,
Smoking Cessation
Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo
NCT00749944
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now